The Europe Pancrelipase Market would witness market growth of 4.5% CAGR during the forecast period (2023-2030).
An increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer is the major factor driving the market growth. People's lifestyles are quickly evolving in the modern era; they are moving toward a new, harmful way of life, including an unhealthy diet. This medicine helps treat poor digestion caused by many digestive system-related disorders. Thus, increasing gastrointestinal diseases due to changing lifestyles people drive market growth.
In addition, this drug is the primary treatment for exocrine pancreatic insufficiency. It is a disorder characterized by a lack of exocrine pancreatic enzymes, which causes maldigestion or an inability to digest food effectively. In this condition, the pancreas cannot produce enough digestive enzymes. Exocrine pancreatic insufficiency can arise from a range of pathological conditions, such as cystic fibrosis, chronic pancreatitis, post-pancreatectomy, gastrointestinal bypass surgery, and pancreatic malignancy. The increasing incidence of these diseases propels the market growth.
The International Trade Administration projects that the medical device sector in France will generate an anticipated €36.7 billion in revenue by 2022. The industry turnover for medical devices exported from France is estimated at €9.4 billion, 26% of the total industry. The industry is expected to see an annual growth of about 2% for the next several years. The aging population necessitates an expansion of senior healthcare services in France. Geriatric clinics and specialized care facilities are crucial in diagnosing and managing pancreatic disorders, contributing to the demand for this drug. Due to the aforementioned factors the market growth will drive in this region.
The Germany market dominated the Europe Pancrelipase Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $153.4 Million by 2030. The UK market is exhibiting a CAGR of 3.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.3% during (2023 - 2030).
Free Valuable Insights: The Global Pancrelipase Market will Hit $2.6 Billion by 2030, at a CAGR of 4.7%
Based on Age, the market is segmented into Adults & Geriatrics, and Children. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on Application, the market is segmented into Chronic Pancreatitis, Cystic Fibrosis, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
By Age
By Distribution Channel
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
